LONDON, GREATER LONDON, UNITED KINGDOM, January 22, 2025 /EINPresswire / -- What has been the historic growth trend in the abrysvo or arexvy global market and what is expected in the coming years?

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

Shares were also aided by a successful US and European launch of Arexvy, a respiratory syncytial virus (RSV) vaccine for older adults. Although risks around the Zantac litigation remain a concern ...

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

A good performance by its HIV business, as well as respiratory syncytial virus (RSV) vaccine Arexvy and myelofibrosis therapy Omjjara/Ojjaara (momelotinib) – both launched within the last 12 ...